Organization: Neuromed Pharmaceuticals Ltd

Neuromed strikes major R&D deal with Merck

Neuromed Pharmaceuticals Ltd has signed an R&D collaboration and licencing agreement with Merck & Co Inc worth up to US$475 million if the Vancouver-based firm is successful in developing a new generation of pain killers and reaches milestones for four indications of its NMED-160 compound for pain treatment. The deal closely follows Neuromed’s completion of…